Immunome (NASDAQ:IMNM) Sets New 12-Month Low - Here's What Happened

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.12 and last traded at $8.15, with a volume of 960264 shares changing hands. The stock had previously closed at $8.18.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Stephens reissued an "overweight" rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price target on the stock. Finally, Guggenheim dropped their price objective on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $25.50.

Immunome Stock Down 4.0 %

The stock has a market capitalization of $607.79 million, a P/E ratio of -0.86 and a beta of 1.93. The firm has a 50-day moving average of $9.56 and a 200 day moving average of $11.38.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Transactions at Immunome

In other news, CTO Philip Tsai bought 12,300 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $8.42 per share, with a total value of $103,566.00. Following the completion of the transaction, the chief technology officer now owns 33,300 shares of the company's stock, valued at $280,386. This trade represents a 58.57 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime acquired 7,000 shares of the company's stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $8.21 per share, with a total value of $57,470.00. Following the purchase, the director now directly owns 23,615 shares in the company, valued at approximately $193,879.15. This represents a 42.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 306,400 shares of company stock valued at $2,322,995 over the last three months. Company insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its holdings in shares of Immunome by 6.6% during the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after purchasing an additional 1,520 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Immunome by 11.7% in the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company's stock valued at $202,000 after acquiring an additional 2,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Immunome by 5.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company's stock worth $441,000 after acquiring an additional 2,005 shares in the last quarter. Intech Investment Management LLC grew its position in Immunome by 26.5% in the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company's stock valued at $201,000 after purchasing an additional 3,974 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after purchasing an additional 4,874 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.